Search

everythinglearnresearchcommunity

for

Search:↓

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

New compounds called benzoquinolinones may treat conditions linked to excess DHT.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

Removing myelin protein zero-like 3 in mice leads to better metabolism and resistance to obesity.

Some newly made compounds can block an enzyme linked to hair loss and prostate growth, with one in particular being very selective.

Negative expectations can cause adverse effects in dermatology treatments, like with finasteride for baldness, and careful communication can help reduce these nocebo responses.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

Scientists made a carbon-14 labeled version of a drug with a 48% yield and over 99% purity.

Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.

Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.

All four treatments for early rheumatoid arthritis had similar safety profiles.

Low dose methotrexate does not increase hair fall and may reduce it.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Baricitinib is effective and safe for treating severe alopecia areata.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Most patients with frontal fibrosing alopecia stabilized with treatment, especially younger ones, using intralesional corticosteroids and tacrolimus.

Dupilumab for atopic dermatitis may cause new or worsen existing alopecia areata.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.